

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A cancer vaccine containing as an active ingredient an antigen-specific dendritic cell pulsed by an HM1.24 protein or HM1.24 peptide, and wherein the vaccine is used as a therapeutic.
2. (Canceled).
3. (Previously Presented) A cancer vaccine according to Claim 1 wherein said HM1.24 peptide is a soluble HM1.24 peptide.
- 4 -11. (Canceled).
12. (Previously Presented) A cancer vaccine according to Claim 1, wherein said cancer is a cancer of an organ or tissue which expresses an HM1.24 antigen.
- 13 -22. (Canceled).
23. (Previously Presented) A cancer vaccine according to Claim 3, wherein the soluble HM1.24 peptide has the amino acid sequence shown in SEQ ID NO: 16 or SEQ ID NO: 17.
24. (Previously Presented) A method according to claim 1, wherein the method comprises the steps of:
  - (a) pulsing immature dendritic cells by an HM1.24 protein or HM1.24 peptide;
  - (b) accomplishing the maturation; and
  - (c) administering mature dendritic cells into patient.
25. (Previously Presented) A cancer vaccine according to claim 1, wherein the dendritic cell serves as an antigen-presenting cell for a helper T cell.

26. (Previously Presented) A method for generating T cell, which comprises administering an antigen-specific dendritic cell pulsed by an HM1.24 protein or HM1.24 peptide.
27. (Previously Presented) A method according to claim 26, wherein said HM1.24 peptide is a soluble HM1.24 peptide.
28. (Previously Presented) A method according to claim 26, wherein said cancer is a cancer of an organ or tissue which expresses an HM1.24 antigen.
29. (Previously Presented) A method according to claim 27, wherein the soluble HM1.24 peptide has the amino acid sequence shown in SEQ ID NO: 16 or SEQ ID NO: 17.
30. (Previously Presented) A method according to claim 26, wherein the method comprises the steps of:
- (a) pulsing immature dendritic cells by an HM1.24 protein or HM1.24 peptide;
  - (b) accomplishing the maturation; and
  - (c) administering mature dendritic cells into patient.
31. (Previously Presented) A method according to claim 26, wherein the dendritic cell serves as an antigen-presenting cell for a helper T cell.
32. (New) A cancer vaccine according to claim 1, wherein the vaccine is produced by a process comprising:
- (a) pulsing immature dendritic cells by an HM1.24 protein or HM1.24 peptide, and
  - (b) accomplishing the maturation.